Kyverna Therapeutics (NASDAQ:KYTX) Raised to “Hold” at Wall Street Zen

by · The Markets Daily

Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Several other research firms have also weighed in on KYTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Monday, December 8th. William Blair initiated coverage on shares of Kyverna Therapeutics in a research note on Wednesday, August 20th. They issued an “outperform” rating on the stock. Wells Fargo & Company increased their price objective on Kyverna Therapeutics from $27.00 to $31.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. Morgan Stanley boosted their target price on Kyverna Therapeutics from $20.00 to $25.00 and gave the company an “overweight” rating in a research note on Thursday, December 4th. Finally, HC Wainwright upped their target price on Kyverna Therapeutics from $10.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday, October 27th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $25.33.

Check Out Our Latest Stock Report on KYTX

Kyverna Therapeutics Trading Up 5.0%

NASDAQ:KYTX opened at $8.78 on Friday. The business’s fifty day moving average price is $7.19 and its 200 day moving average price is $5.00. The firm has a market capitalization of $384.56 million, a price-to-earnings ratio of -2.35 and a beta of 3.65. Kyverna Therapeutics has a 1-year low of $1.78 and a 1-year high of $9.75.

Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.12. Equities analysts forecast that Kyverna Therapeutics will post -3.29 earnings per share for the current year.

Hedge Funds Weigh In On Kyverna Therapeutics

Several large investors have recently added to or reduced their stakes in KYTX. Public Employees Retirement System of Ohio bought a new stake in shares of Kyverna Therapeutics in the 3rd quarter worth approximately $28,000. Capital Advisors Inc. OK acquired a new position in shares of Kyverna Therapeutics in the third quarter valued at $60,000. Phoenix Wealth Advisors bought a new position in Kyverna Therapeutics in the second quarter worth $32,000. Catalyst Funds Management Pty Ltd bought a new position in Kyverna Therapeutics in the second quarter worth $37,000. Finally, Ameriprise Financial Inc. acquired a new stake in Kyverna Therapeutics during the third quarter worth $77,000. Institutional investors and hedge funds own 18.08% of the company’s stock.

Kyverna Therapeutics Company Profile

(Get Free Report)

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.

Recommended Stories